Navigation Links
Questcor Pharmaceuticals Accelerates Cash Dividend; Payment Date Set for December 21, 2012
Date:12/4/2012

ANAHEIM, Calif., Dec. 4, 2012 /PRNewswire/ -- Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today announced that its Board of Directors has declared a quarterly cash dividend of $0.20 per share to all shareholders of record at the close of business on December 14, 2012.  The dividend will be paid in lieu of the Company's regular quarterly cash dividend that would have been paid in the first quarter of 2013, and is scheduled to be paid on or about December 21, 2012.  The Company accelerated payment of the first quarter 2013 dividend to allow its shareholders to benefit from the current dividend tax rate that is scheduled to expire on December 31, 2012.  Future dividends will be at the discretion of the Board of Directors.

"Our business continues to grow and this dividend reflects our positive outlook and confidence in our ability to continue to generate returns for shareholders and invest in future growth through R&D," said Don M. Bailey, President and CEO of Questcor.

About Questcor 

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the treatment of patients with serious, difficult-to-treat autoimmune and inflammatory disorders.  Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications.  Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of proteinuria in idiopathic types of nephrotic syndrome, the treatment of acute exacerbations of multiple sclerosis in adults, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathi
'/>"/>

SOURCE Questcor Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Questcor Pharmaceuticals to Present at JMP Securities Healthcare Conference
2. Questcor to Report Second Quarter Results on July 24, 2012
3. Questcor Reports Second Quarter Financial Results
4. Questcor Pharmaceuticals to Present at Investor Conferences in September
5. Questcor and The Myositis Association Team Up To Support Research and Educational Initiatives in Polymyositis and Dermatomyositis
6. Questcor Comments on Insurance Policy Bulletin
7. Questcor to Conduct Conference Call to Discuss Reimbursement Process
8. Harwood Feffer LLP Announces Investigation of Questcor Pharmaceuticals, Inc.
9. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
10. Auxilium Pharmaceuticals to Present at the Deutsche Bank 37th Annual Healthcare Conference
11. Nouveau Life Pharmaceuticals (HRID) Contracts with U.S. Manufacturer to Produce New Female Supplement
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... 23, 2014 PuraMed BioScience®, Inc., (OTC Pink: ... medicinal and healthcare products, announced it received the initial ... hemp-based, advanced headache relief product, for planned distribution to ... Colorado , Washington State , ... the MigraPure H Advanced headache relief gel formulation completed, ...
(Date:12/24/2014)... Dec. 23, 2014   Synageva BioPharma Corp. ... company developing therapeutic products for rare disorders, today ... of the Marketing Authorization Application (MAA) for sebelipase ... the company,s request for accelerated assessment, which has ... time.   The MAA, and the ...
(Date:12/24/2014)... Calif. , Dec. 23, 2014 In response ... Doctors, Association of Sierra Leone , Direct ... Leone for the treatment of local health workers ... While a new dedicated Ebola care center was constructed for ... the facility is not available for local Sierra Leonean health ...
Breaking Medicine Technology:PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 2Synageva BioPharma Announces Sebelipase Alfa Marketing Authorization Application Validated By The EMA 3First Ebola Treatment Unit for Local Health Workers Arrives in Sierra Leone 2
... RAD001 reduces risk of disease progression by 70%, - RAD001 is first and ... Nexavar(R),** with potential to address ... unmet medical need,- Once-daily oral RAD001 directly targets ... and blood vessel growth, - RAD001 is currently being studied in multiple types ...
... Adding Singulair to Advair Offers no Additional ... Improvement in Overall Asthma ... 18 /PRNewswire-FirstCall/,-- Patients with both asthma and allergic rhinitis, ... with Advair,Diskus(R) (fluticasone propionate and salmeterol inhalation powder) as,compared ...
Cached Medicine Technology:RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 2RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 3RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 4RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 5RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer 6Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM) 2Patients With Asthma and Seasonal Allergies Respond Better to Advair(R) for Their Asthma Than Singulair(TM) 3
(Date:12/25/2014)... California (PRWEB) December 25, 2014 Plugin ... of ProFire 5k. A fully customizable business presentation tool ... , “Adding the ProFire 5k business tool, users can ... Christina Austin, CEO of Pixel Film Studios. “ProFire 5k ... and style to add professionalism to a presentation” , ...
(Date:12/25/2014)... AZ (PRWEB) December 25, 2014 Parker ... to outstanding customer service and affordable quality regarding heating, ... area announces recognition in 2014 by the “Queen of ... Sons has earned an impressive reputation over the years ... on a wide range of contractor services for both ...
(Date:12/24/2014)... Epigenetics finds applications in a large ... drug discovery, developmental biology, and research for metabolic and ... the most widely used techniques for the discovery and ... of cancer is rapidly growing worldwide. In 2012, there ... deaths, and 32.6 million people living with cancer (within ...
(Date:12/24/2014)... 2014 Risperdal lawsuit ( http://www.risperdallawsuit2014.com/ ) ... litigation currently underway in Pennsylvania’s Philadelphia Court of Common ... 24, 2014, court documents indicate that 1,183 claims had ... who developed gynecomastia (male breast growth) and other complications ... indicates that this represents an increase of more than ...
(Date:12/24/2014)... 2014 The federal court overseeing ... blood thinner caused life-threatening episodes of internal bleeding ... for the proceeding, Bernstein Liebhard LLP reports. According ... plans to select lawyers to serve as Liaison ... appointing a Plaintiffs’ Steering Committee, which will coordinate ...
Breaking Medicine News(10 mins):Health News:Announcing a new ProFire 5k plugin from Pixel Film Studios for Final Cut Pro X Professionals 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 2Health News:Parker & Sons Announces Recognition In 2014 By The “Queen Of Clean” For Impressive Contractor Services In Arizona 3Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 2Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 3Health News:Risperdal Lawsuits Continue to Climb, as Claims in Pennsylvania Litigation Exceed 1,180 Filings, Bernstein Liebhard LLP Reports 4Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 2Health News:Court Overseeing Federal Xarelto Lawsuits Issues Coordination Order, Bernstein Liebhard LLP Reports 3
... Uroplasty, Inc. (Amex:,UPI) announced today that it ... Fourth Annual Equity Conference which will be held ... the Loews Lake Las Vegas Resort, NV.,Dave Kaysen, ... Vice,President and Chief Financial Officer will discuss the ...
... Aug. 11 ,BlueCross BlueShield of Tennessee (BCBS-T) has ... settle allegations of violating the False Claims,Act, the ... Chattanooga, Tenn., operates as Riverbend Government Benefit,Administrators., ... primary,Medicare Part A Fiscal Intermediary for the state ...
... access and practical ... ... for medical professionals, today announced the availability,of PubMed,s MEDLINE abstracts at ... U.S. National Library,of Medicine,s MEDLINE index. SearchMedica,s MEDLINE abstracts link back ...
... Nation Using Caregiverlist.com to Find Quality ... ... nation,s online,destination dedicated to connecting seniors with quality senior care,choices, is ... care services as the caregiving recruitment source for the,industry. Nearly 1,000 ...
... Cardiovascular Disease (GICD) and UCSF have identified a key ... system, the extensive network of arteries, veins, and ... organs. The research, published in the latest issue of ... therapeutic targets for a wide variety of diseases, such ...
... Cincinnati Sub-Zero Medical receives Governor,s 2008 Excellence in Exporting Award (,E-Award,), ... Strickland and Lieutenant Governor Lee Fisher present award to CSZ Chairman ... ... August 11, 2008 -- Cincinnati Sub-Zero (CSZ) Medical, a division of ...
Cached Medicine News:Health News:Uroplasty to Present at the Noble Financial Fourth Annual Equity Conference 2Health News:BlueCross BlueShield of Tennessee to Pay U.S. $2.1 Million to Resolve False Claims Act Allegations 2Health News:SearchMedica.com Connects Medical Professionals With MEDLINE Abstracts 2Health News:Home Care Agencies Staffing Challenge Solved With Caregiverlist.com 2Health News:Gladstone scientists identify single microRNA that controls blood vessel development 2Health News:Gladstone scientists identify single microRNA that controls blood vessel development 3Health News:State of Ohio Recognizes Cincinnati Sub-Zero for Excellence in International Sales 2Health News:State of Ohio Recognizes Cincinnati Sub-Zero for Excellence in International Sales 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: